- Home
- FLYE vs CURX Comparison
FLYE vs CURX Comparison
Compare FLYE & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | CURX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 11.6M |
| IPO Year | 2024 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FLYE | CURX |
|---|---|---|
| Price | $1.94 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.0K | ★ 5.6M |
| Earning Date | 01-01-0001 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,427,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.26 |
| 52 Week High | $21.80 | $9.18 |
Technical Indicators
Market Signals| Indicator | FLYE | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 51.48 |
| Support Level | $1.80 | $0.39 |
| Resistance Level | $5.87 | $0.42 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 21.23 | 24.80 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.